Wendy Onstenk

2.6k total citations
25 papers, 813 citations indexed

About

Wendy Onstenk is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Wendy Onstenk has authored 25 papers receiving a total of 813 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 14 papers in Cancer Research. Recurrent topics in Wendy Onstenk's work include Cancer Genomics and Diagnostics (12 papers), Cancer Cells and Metastasis (11 papers) and Prostate Cancer Treatment and Research (10 papers). Wendy Onstenk is often cited by papers focused on Cancer Genomics and Diagnostics (12 papers), Cancer Cells and Metastasis (11 papers) and Prostate Cancer Treatment and Research (10 papers). Wendy Onstenk collaborates with scholars based in Netherlands, Belgium and Italy. Wendy Onstenk's co-authors include Stefan Sleijfer, John A. Foekens, Jaco Kraan, Anieta M. Sieuwerts, John W.M. Martens, Paul Hamberg, Ronald de Wit, Luc Dirix, Martijn P. Lolkema and Mai N. Van and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

Wendy Onstenk

24 papers receiving 806 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wendy Onstenk Netherlands	19	456	455	397	257	86	25	813
Mateus Crespo United Kingdom	17	393 0.9×	421 0.9×	525 1.3×	399 1.6×	97 1.1×	44	1.0k
Gretchen A. Gignac United States	9	286 0.6×	481 1.1×	382 1.0×	122 0.5×	115 1.3×	21	757
Leonie Voorwerk Netherlands	10	298 0.7×	743 1.6×	338 0.9×	238 0.9×	37 0.4×	17	1.0k
Hyesil Seol South Korea	15	307 0.7×	480 1.1×	244 0.6×	264 1.0×	207 2.4×	34	853
Bram De Laere Belgium	14	438 1.0×	339 0.7×	519 1.3×	232 0.9×	115 1.3×	35	793
Adam Jendrisak United States	10	518 1.1×	510 1.1×	679 1.7×	255 1.0×	104 1.2×	32	988
Yien Ning Sophia Wong United Kingdom	8	284 0.6×	687 1.5×	350 0.9×	387 1.5×	75 0.9×	17	1.1k
Dzifa Y. Duose United States	16	239 0.5×	170 0.4×	195 0.5×	261 1.0×	19 0.2×	45	698
Sophia L. Maund United States	13	180 0.4×	360 0.8×	222 0.6×	368 1.4×	49 0.6×	31	815
B. Lisboa Germany	12	376 0.8×	474 1.0×	100 0.3×	203 0.8×	97 1.1×	23	788

Countries citing papers authored by Wendy Onstenk

Since Specialization

Citations

This map shows the geographic impact of Wendy Onstenk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wendy Onstenk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wendy Onstenk more than expected).

Fields of papers citing papers by Wendy Onstenk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wendy Onstenk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wendy Onstenk. The network helps show where Wendy Onstenk may publish in the future.

Co-authorship network of co-authors of Wendy Onstenk

This figure shows the co-authorship network connecting the top 25 collaborators of Wendy Onstenk. A scholar is included among the top collaborators of Wendy Onstenk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wendy Onstenk. Wendy Onstenk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pol, Ymke van der, Norbert Moldován, Sandra A.W.M. Verkuijlen, et al.. (2022). The Effect of Preanalytical and Physiological Variables on Cell-Free DNA Fragmentation. Clinical Chemistry. 68(6). 803–813. 29 indexed citations

Sieuwerts, Anieta M., Esther Oomen‐de Hoop, Bianca Mostert, et al.. (2019). Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer. European Journal of Cancer. 121. 48–54. 23 indexed citations

Sieuwerts, Anieta M., Wendy Onstenk, Jaco Kraan, et al.. (2019). Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel. Cancers. 11(8). 1212–1212. 21 indexed citations

Nanou, Afroditi, Frank Coumans, Guus van Dalum, et al.. (2018). Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients. Oncotarget. 9(27). 19283–19293. 54 indexed citations

Sieuwerts, Anieta M., Bianca Mostert, Michelle van der Vlugt‐Daane, et al.. (2018). An In-Depth Evaluation of the Validity and Logistics Surrounding the Testing of AR-V7 mRNA Expression in Circulating Tumor Cells. Journal of Molecular Diagnostics. 20(3). 316–325. 15 indexed citations

Beije, Nick, Jaco Kraan, Mai N. Van, et al.. (2017). Abstract P1-02-02: ESR1 mutations in circulating tumor cell versus circulating cell-free DNA of metastatic breast cancer patients before first-line endocrine therapy and at progression. Cancer Research. 77(4_Supplement). P1–2.

Beije, Nick, Anieta M. Sieuwerts, Jaco Kraan, et al.. (2017). Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients. Molecular Oncology. 12(1). 48–57. 50 indexed citations

Beije, Nick, Wendy Onstenk, Jaco Kraan, et al.. (2016). Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor. Neoplasia. 18(11). 647–653. 40 indexed citations

Sieuwerts, Anieta M., Marcel Smid, Joan Bolt‐de Vries, et al.. (2016). An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients. BMC Cancer. 16(1). 123–123. 21 indexed citations

10.

Onstenk, Wendy, et al.. (2016). The use of circulating tumor cells in guiding treatment decisions for patients with metastatic castration-resistant prostate cancer. Cancer Treatment Reviews. 46. 42–50. 26 indexed citations

11.

Onstenk, Wendy, Anieta M. Sieuwerts, Bianca Mostert, et al.. (2016). Molecular characteristics of circulating tumor cells resemble the liver metastasis more closely than the primary tumor in metastatic colorectal cancer. Oncotarget. 7(37). 59058–59069. 34 indexed citations

12.

Onstenk, Wendy, Anieta M. Sieuwerts, Jaco Kraan, et al.. (2015). Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells. European Urology. 68(6). 939–945. 195 indexed citations

13.

Lalmahomed, Zarina S., Bianca Mostert, Wendy Onstenk, et al.. (2015). Prognostic value of circulating tumour cells for early recurrence after resection of colorectal liver metastases. British Journal of Cancer. 112(3). 556–561. 27 indexed citations

14.

Onstenk, Wendy, Jaco Kraan, Bianca Mostert, et al.. (2014). Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. Molecular Cancer Therapeutics. 14(3). 821–827. 47 indexed citations

15.

Burg, M.E.L. van der, Wendy Onstenk, Ingrid Boere, et al.. (2014). Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer. European Journal of Cancer. 50(15). 2592–2601. 28 indexed citations

16.

Peeters, Dieter, Anja Brouwer, Gert G. Van den Eynden, et al.. (2014). Circulating tumour cells and lung microvascular tumour cell retention in patients with metastatic breast and cervical cancer. Cancer Letters. 356(2). 872–879. 25 indexed citations

17.

Onstenk, Wendy, J.W. Gratama, John A. Foekens, & Stefan Sleijfer. (2013). Towards a personalized breast cancer treatment approach guided by circulating tumor cell (CTC) characteristics. Cancer Treatment Reviews. 39(7). 691–700. 59 indexed citations

18.

Burg, M.E.L. van der, Ignace Vergote, Wendy Onstenk, et al.. (2012). Long-term results of weekly paclitaxel carboplatin induction therapy: An effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer. European Journal of Cancer. 49(6). 1254–1263. 23 indexed citations

19.

Strijbos, Michiel, Jan W. Gratama, Paul Schmitz, et al.. (2010). Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel. European Journal of Cancer. 46(11). 2027–2035. 42 indexed citations

20.

Burg, Matthias, Jan Janßen, Petronella B. Ottevanger, et al.. (2009). Multicenter randomized phase III trial of 3-weekly paclitaxel/platinum (PC3w) versus weekly paclitaxel/platinum (PCw) induction therapy followed by PC3w maintenance therapy in advanced epithelial ovarian cancer (EOC). Journal of Clinical Oncology. 27(15_suppl). 5538–5538. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact